Amedisys (NASDAQ:AMED) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Amedisys (NASDAQ:AMED - Get Free Report) released its quarterly earnings results on Wednesday. The health services provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01, Briefing.com reports. Amedisys had a negative net margin of 0.44% and a positive return on equity of 12.76%. The company had revenue of $571.41 million for the quarter, compared to analyst estimates of $565.38 million. During the same period last year, the firm earned $1.00 earnings per share. The firm's revenue was up 2.7% on a year-over-year basis.

Amedisys Stock Performance

AMED stock traded up $0.11 during mid-day trading on Thursday, hitting $91.16. The company had a trading volume of 236,321 shares, compared to its average volume of 277,878. The stock's fifty day moving average price is $92.57 and its two-hundred day moving average price is $93.35. Amedisys has a 12 month low of $73.10 and a 12 month high of $96.44. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.05 and a current ratio of 1.05. The firm has a market cap of $2.98 billion, a PE ratio of -294.06, a price-to-earnings-growth ratio of 4.29 and a beta of 0.86.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on AMED shares. StockNews.com started coverage on shares of Amedisys in a research report on Monday, April 8th. They set a "buy" rating on the stock. Royal Bank of Canada raised their price target on shares of Amedisys from $97.00 to $100.00 and gave the company an "outperform" rating in a research report on Monday, March 25th. Cantor Fitzgerald reissued a "neutral" rating and set a $101.00 price target on shares of Amedisys in a research report on Thursday. Finally, Raymond James reissued a "market perform" rating on shares of Amedisys in a research report on Tuesday, March 26th. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Amedisys has an average rating of "Hold" and a consensus target price of $97.50.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.